Associate ProfessorMichał Antoszczak
Dr Michał Antoszczak obtained a PhD degree in chemical sciences in 2016 and since 2017 he has been employed as an assistant professor at the Faculty of Chemistry, Adam Mickiewicz University in Poznań, Poland. His scientific interests are related to the chemical modification of natural products in the context of their potential use in anticancer or antimicrobial therapies. He completed research internships at leading European research centers, such as Lund University (Sweden) and Institut Curie in Paris (France), and was a beneficiary of prestigious scientific scholarships, including the scholarship of the Polish Minister of Science and Higher Education for outstanding young scientists and the START stipend of the Foundation for Polish Science. So far, Dr Michał Antoszczak has published >50 articles in the journals from the JCR list
ORCiD: 0000-0003-0877-1726
Web of Science ID: JBJ-0906-2023
https://adhucz.home.amu.edu.pl/
Since 2014 ‒ a member of the Polish Chemical Society
2020‒2024 ‒ a member of the Scientific Council of Discipline of Chemical Sciences
- Medicinal chemistry;
- (bio)organic chemistry;
- chemical biology;
- natural product chemistry;
- prodrugs synthesis;
- polyether ionophores;
- steroidal iron chelators;
- anticancer activity;
- antibacterial activity;
- antiparasitic activity;
- structure-activity relationship;
- spectroscopic analysis
[1] Antoszczak M., Müller S., Cañeque T., Colombeau L., Dusetti N., Santofimia-Castaño P., Gaillet C., Puisieux A., Iovanna J.L., Rodriguez R. (2022) Iron-sensitive prodrugs that trigger active ferroptosis in drug-tolerant pancreatic cancer cells, J. Am. Chem. Soc. 144, 11536‒11545
[2] Antoszczak M., Müller S., Colombeau L., Cañeque T., Rodriguez R. (2022) Rapid access to ironomycin derivatives by click chemistry, ACS Org. Inorg. Au 2, 222‒228
[3] Antoszczak M., Otto-Ślusarczyk D., Kordylas M., Struga M., Huczyński A. (2022) Synthesis of lasalocid-based bioconjugates and evaluation of their anticancer activity, ACS Omega 7, 1943–1955
[4] Antoszczak M., Steverding D., Sulik M., Janczak J., Huczyński A. (2019) Anti-trypanosomal activity of doubly modified salinomycin derivatives, Eur. J. Med. Chem. 173, 90–98
[5] Antoszczak M. (2019) A medicinal chemistry perspective on salinomycin as a potent anticancer and anti-CSCs agent, Eur. J. Med. Chem. 164, 366–377
[6] Antoszczak M., Urbaniak A., Delgado M., Maj E., Borgström B., Wietrzyk J., Huczyński A., Yuan Y., Chambers T.C., Strand D. (2018) Biological activity of doubly modified salinomycin analogs – Evaluation in vitro and ex vivo, Eur. J. Med. Chem. 156, 510–523